First Time Loading...

Vivos Therapeutics Inc
NASDAQ:VVOS

Watchlist Manager
Vivos Therapeutics Inc Logo
Vivos Therapeutics Inc
NASDAQ:VVOS
Watchlist
Price: 4.83 USD 3.87% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

VVOS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). [ Read More ]

The intrinsic value of one VVOS stock under the Base Case scenario is 27.31 USD. Compared to the current market price of 4.83 USD, Vivos Therapeutics Inc is Undervalued by 82%.

Key Points:
VVOS Intrinsic Value
Base Case
27.31 USD
Undervaluation 82%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Vivos Therapeutics Inc

Backtest VVOS Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling VVOS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Vivos Therapeutics Inc

Current Assets 2m
Cash & Short-Term Investments 990k
Receivables 230k
Other Current Assets 770k
Non-Current Assets 8.3m
PP&E 4.8m
Intangibles 3.3m
Other Non-Current Assets 310k
Current Liabilities 7.2m
Accounts Payable 1.5m
Accrued Liabilities 2.4m
Other Current Liabilities 3.3m
Non-Current Liabilities 3.1m
Other Non-Current Liabilities 3.1m
Efficiency

Earnings Waterfall
Vivos Therapeutics Inc

Revenue
14.5m USD
Cost of Revenue
-5.8m USD
Gross Profit
8.7m USD
Operating Expenses
-27.8m USD
Operating Income
-19.1m USD
Other Expenses
3.7m USD
Net Income
-15.4m USD

Free Cash Flow Analysis
Vivos Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

VVOS Profitability Score
Profitability Due Diligence

Vivos Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
23/100
Profitability
Score

Vivos Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

VVOS Solvency Score
Solvency Due Diligence

Vivos Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
42/100
Solvency
Score

Vivos Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VVOS Price Targets Summary
Vivos Therapeutics Inc

Wall Street analysts forecast VVOS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VVOS is 7.27 USD with a low forecast of 6.06 USD and a high forecast of 8.66 USD.

Lowest
Price Target
6.06 USD
25% Upside
Average
Price Target
7.27 USD
50% Upside
Highest
Price Target
8.66 USD
79% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

VVOS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

VVOS Price
Vivos Therapeutics Inc

1M 1M
-17%
6M 6M
+1%
1Y 1Y
-41%
3Y 3Y
-97%
5Y 5Y
-98%
10Y 10Y
-98%
Annual Price Range
4.83
52w Low
2.74
52w High
41
Price Metrics
Average Annual Return -54.2%
Standard Deviation of Annual Returns 18.59%
Max Drawdown -99%
Shares Statistics
Market Capitalization 6.4m USD
Shares Outstanding 1 331 980
Percentage of Shares Shorted 2.04%

VVOS Return Decomposition
Main factors of price return

What is price return decomposition?

VVOS News

Last Important Events
Vivos Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Vivos Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Vivos Therapeutics Inc Logo
Vivos Therapeutics Inc

Country

United States of America

Industry

Health Care

Market Cap

6.4m USD

Dividend Yield

0%

Description

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Highlands Ranch, Colorado and currently employs 158 full-time employees. The company went IPO on 2020-12-11. The firm is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The firm's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.

Contact

COLORADO
Highlands Ranch
9137 Ridgeline Boulevard, Suite 135
+18669084867.0
https://www.vivoslife.com/

IPO

2020-12-11

Employees

158

Officers

Co-Founder, Chairman of the Board & CEO
Mr. R. Kirk Huntsman
CFO, Treasurer & Secretary
Mr. Bradford K. Amman
Co-Founder & Senior VP of Product and Technology
Mr. Todd Huntsman
Co-Founder and Senior VP of Events & Clinical Advisory Services
Ms. RaeAnn Byrnes
Co-Founder & Executive VP of Operations
Ms. Susan McCullough
Senior VP of Strategic Sales & Marketing and Investor Relations Officer
Ms. Julie Gannon
Show More
Senior Vice President of Medical Integration Division
Mr. Nicholas M. DeGennaro
Senior Vice President of Practice Services
Ms. Ruth Hembree
Senior Vice President of Dental Service Integration
Ms. Stephanie Huebner
Senior Vice President of Technology
Mr. John Ballard
Show Less

See Also

Discover More
What is the Intrinsic Value of one VVOS stock?

The intrinsic value of one VVOS stock under the Base Case scenario is 27.31 USD.

Is VVOS stock undervalued or overvalued?

Compared to the current market price of 4.83 USD, Vivos Therapeutics Inc is Undervalued by 82%.